title: pCR proves valid surrogate endpoint.
abstract: Results from the randomized, phase III NeoALTTO trial, presented at the 2013 San Antonio Breast Cancer Symposium in December, support the idea that pathologic complete response is a valid surrogate endpoint for the effectiveness of long-term neoadjuvant treatment of breast cancer.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers